Ad
related to: serotonin transporter gene and depression treatment pdf download ppt filem4.havenhealthmgmt.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
5-HTTLPR (serotonin-transporter-linked promoter region) is a degenerate repeat (redundancy in the genetic code) polymorphic region in SLC6A4, the gene that codes for the serotonin transporter. Since the polymorphism was identified in the middle of the 1990s, [ 1 ] [ 2 ] it has been extensively investigated, e.g., in connection with ...
The serotonin transporter (SERT or 5-HTT) also known as the sodium-dependent serotonin transporter and solute carrier family 6 member 4 is a protein that in humans is encoded by the SLC6A4 gene. [5] SERT is a type of monoamine transporter protein that transports the neurotransmitter serotonin from the synaptic cleft back to the presynaptic ...
BDNF is involved in depression through its effects on serotonin. BDNF has been shown to promote the development, function, and expression of serotonergic neurons. [28] Because more active serotonin results in more positive moods, antidepressants work to increase serotonin levels.
First, serotonin system dysfunction cannot be the sole cause of depression, because not all patients treated with antidepressants show improvement, despite the fact that most patients still show a rapid increase in synaptic serotonin. Second, if significant mood improvements do occur, this is often not for at least two to four weeks.
The pharmacology of antidepressants is not entirely clear.. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis (which can be traced back to the 1950s), which states that depression is due to an imbalance (most often a deficiency) of the monoamine neurotransmitters (namely serotonin, norepinephrine and dopamine). [1]
The 7 general serotonin receptor classes include a total of 14 known serotonin receptors. [9] The 15th receptor 5-HT 1P has been distinguished on the basis of functional and radioligand binding studies, its existence has never been definitely affirmed or refuted. [10] [11] The specific types have been characterized as follows: [12] [13] [14]
There is also clinical evidence of the value of SSRIs in the treatment of the symptoms of schizophrenia and their ability to prevent cardiovascular diseases. [1] SSRIs primarily inhibit serotonin transporter (SERT) in the brain and have negligible effects on dopamine transporter (DAT) and norepinephrine transporter (NET).
A monoamine reuptake inhibitor (MRI) [1] is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine by blocking the action of one or more of the respective monoamine transporters (MATs), which include the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT).